Google
NGNE — NEUROGENE INC (Healthcare >> Biotechnology)
NGNE FAQ
What is NGNE's ROE?
NEUROGENE INC reports a Return on Equity (ROE) of -41.48%.
What is NGNE's dividend yield?
NEUROGENE INC offers a dividend yield of 0.00%.
What is NGNE's Deepscope Quality Score?
Deepscope rates NGNE's overall financial quality at 0 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NGNE?
Deepscope's AI Timing Score for NGNE is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NGNE belong to?
NEUROGENE INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 26.49
Price
-0.99
(-3.60%)
Day Change
|
|
|---|
NGNE, the overall quality is not good ( Quality = 0) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 26.49 |
| PBV / Sector |
1.74 / 4.63
|
| Earning Per Share | -6.33 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
3.30 M
GREAT
|
| Average 1W Daily Value |
2.20 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:04 |
| Symbol | NGNE |
| Name | NEUROGENE INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 15.80 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 413.06 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 535 W 24th Street, New York, NY, United States, 10011
Phone: 855 508 3568
Website: https://www.neurogene.com
Employees: 131
Sector: Healthcare >> Biotechnology
Description: Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
